UY39455A - Moduladores del regulador de conductancia transmembranario de la fibrosis quística - Google Patents
Moduladores del regulador de conductancia transmembranario de la fibrosis quísticaInfo
- Publication number
- UY39455A UY39455A UY0001039455A UY39455A UY39455A UY 39455 A UY39455 A UY 39455A UY 0001039455 A UY0001039455 A UY 0001039455A UY 39455 A UY39455 A UY 39455A UY 39455 A UY39455 A UY 39455A
- Authority
- UY
- Uruguay
- Prior art keywords
- modulators
- cystic fibrosis
- conductance regulator
- transmembrane conductance
- fibrosis transmembrane
- Prior art date
Links
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title abstract 3
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063088636P | 2020-10-07 | 2020-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39455A true UY39455A (es) | 2022-05-31 |
Family
ID=78483539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039455A UY39455A (es) | 2020-10-07 | 2021-10-07 | Moduladores del regulador de conductancia transmembranario de la fibrosis quística |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230365587A1 (es) |
EP (1) | EP4225762A1 (es) |
AR (1) | AR123705A1 (es) |
TW (1) | TW202222306A (es) |
UY (1) | UY39455A (es) |
WO (1) | WO2022076618A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
TW202333699A (zh) | 2022-02-03 | 2023-09-01 | 美商維泰克斯製藥公司 | 囊腫纖維化之治療方法 |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
WO2024056779A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
RS53895B1 (en) | 2004-06-24 | 2015-08-31 | Vertex Pharmaceuticals Incorporated | ATP-BINDING CASSETTE TRANSPORT MODULATORS |
PT1945632E (pt) | 2005-11-08 | 2013-12-24 | Vertex Pharma | Moduladores heterocíclicos de transportadores de cassete de ligação a atp |
PL3219705T3 (pl) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
WO2007134279A2 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
SI2639224T1 (sl) | 2007-12-07 | 2016-12-30 | Vertex Pharmaceuticals Incorporated | Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin |
DK3170818T3 (da) | 2007-12-07 | 2020-04-14 | Vertex Pharma | Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre |
RS56894B1 (sr) | 2008-08-13 | 2018-04-30 | Vertex Pharma | Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje |
AR073709A1 (es) | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
CN108117546A (zh) | 2008-11-06 | 2018-06-05 | 弗特克斯药品有限公司 | Atp-结合盒转运蛋白调节剂 |
SI2821400T1 (en) | 2009-03-20 | 2018-02-28 | Vertex Pharmaceuticals Incorporated | A process for the manufacture of a transmembrane conductivity regulator in cystic fibrosis |
EP4253381A3 (en) | 2010-03-25 | 2023-11-01 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]d ioxol-5-yl)-n-(1-(2,3-dihydroxyp ropyl)-6-fluoro-2-(1-hydroxy- 2-methylpropan-2-yl)-1h-indol- 5-yl) cyclopropanecarboxamide |
AU2011237368B2 (en) | 2010-04-09 | 2015-07-23 | Ekso Bionics | Exoskeleton load handling system and method of use |
CN105130948A (zh) | 2010-04-22 | 2015-12-09 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
EP2560649A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
RU2013113627A (ru) | 2010-08-27 | 2014-10-10 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
WO2012158885A1 (en) | 2011-05-18 | 2012-11-22 | Concert Pharmaceuticals Inc. | Deuterated derivatives of ivacaftor |
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
EP2819670A1 (en) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
LT2914248T (lt) | 2012-11-02 | 2018-11-26 | Vertex Pharmaceuticals Incorporated | Farmacinės kompozicijos, skirtos cftr medijuotų ligų gydymui |
MY183582A (en) | 2012-11-19 | 2021-02-26 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
RS57476B9 (sr) | 2014-04-15 | 2021-10-29 | Vertex Pharma | Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze |
US20180353500A1 (en) | 2015-09-21 | 2018-12-13 | Vertex Pharmaceuticals (Europe) Limited | Administration of deuterated cftr potentiators |
WO2018080591A1 (en) | 2016-10-27 | 2018-05-03 | Vertex Pharmaceuticals (Europe) Limited | Methods of treatment with deuterated cftr potentiators |
SI3752510T1 (sl) * | 2018-02-15 | 2023-03-31 | Vertex Pharmaceuticals Incorporated | Makrocikli kot modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki iz le-teh, njihova uporaba pri zdravljenju cistične fibroze in postopek za njihovo proizvodnjo |
UY38630A (es) * | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
CN114599657A (zh) * | 2019-08-14 | 2022-06-07 | 弗特克斯药品有限公司 | Cftr调节剂的结晶形式 |
-
2021
- 2021-10-06 WO PCT/US2021/053853 patent/WO2022076618A1/en unknown
- 2021-10-06 US US18/248,065 patent/US20230365587A1/en active Pending
- 2021-10-06 EP EP21801754.9A patent/EP4225762A1/en active Pending
- 2021-10-07 TW TW110137328A patent/TW202222306A/zh unknown
- 2021-10-07 UY UY0001039455A patent/UY39455A/es unknown
- 2021-10-07 AR ARP210102775A patent/AR123705A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4225762A1 (en) | 2023-08-16 |
WO2022076618A1 (en) | 2022-04-14 |
TW202222306A (zh) | 2022-06-16 |
AR123705A1 (es) | 2023-01-04 |
US20230365587A1 (en) | 2023-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39374A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
UY39456A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
UY39457A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
UY39458A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
UY39459A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
UY39460A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
UY39461A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
UY39455A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
CO2022002749A2 (es) | Moduladores del regulador de conductancia transmembrana de la fibrosis quística | |
CR20230260A (es) | Macrociclos que contienen un anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
UY39521A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |